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CASE REPORT

Successful Treatment of Peritoneal Dialysis Catheter-Related
Polymicrobial Peritonitis Involving Clostridium difficile
Sheena Bharti,a* Prashant Malhotra,a Stefan Juretschkob
Department of Infectious Diseasesa and Department of Microbiology,b Hoftstra North Shore-LIJ School of Medicine, Manhasset, New York, USA

Clostridium difficile is one of the most common nosocomial pathogens and the cause of pseudomembranous colitis in cases of
prior antimicrobial exposure. Extraintestinal manifestations of C. difficile are uncommon and rarely reported. We report the
first successfully treated case of catheter-related C. difficile peritonitis in a patient undergoing peritoneal dialysis.

CASE REPORT

A

72-year-old man was admitted to the hospital with shortness
of breath and abdominal pain for 2 days. His past medical
history was significant for congestive heart failure, hypertension,
and type II diabetes with end-stage nephropathy requiring continuous ambulatory peritoneal dialysis (CAPD). A peritoneal
catheter had been in place for the past 2.5 years.
Upon admission, the patient was afebrile (temperature, 36.7°C),
his blood pressure was 115/62 mm Hg, and his pulse was 59/min. His
abdomen was diffusely tender to palpation, with signs of peritonitis,
but the peritoneal catheter site was unremarkable. Laboratory findings included a hemoglobin level of 11.8 g/dl, total leukocyte count of
12.0 ⫻ 106/liter (79.5% neutrophils), and creatinine level of 12.69
mg/dl. Examination of the peritoneal dialysis (PD) fluid revealed a
white blood cell (WBC) count of 16,000 cells/l with a 93% neutrophil predominance.
One hundred milliliters of PD fluid was transferred into two
50-ml conical tubes and centrifuged for 30 min at 3,000 rpm. After
the supernatant had been discarded, 3 ml of the resuspended sediment from each tube was used for inoculation in a Plus Aerobic/F
blood culture bottle and a Plus Anaerobic/F blood culture bottle
(Bactec, Becton Dickinson, Sparks, MD). All blood culture bottles
were incubated in the Bactec 9240 blood culture system at 35°C for
5 days. Positive blood culture bottles were plated on 5% sheep
blood agar, chocolate agar, and Columbia naladixic acid (CAN)
agar and incubated at 35°C at 5% CO2 for 5 days. In addition,
CDC agar was set up under anaerobic conditions at 35°C, and
thioglycolate broth (enriched) was used to facilitate growth of
anaerobes. All prepared media were purchased from BD BBL
(Becton Dickinson, Sparks, MD).
All 8 blood culture sets containing concentrated peritoneal
dialysis fluid samples from 8 different specimens turned positive within 1 to 4 days. Escherichia coli, Bacterioides fragilis group,
Candida albicans, and Clostridium difficile were identified by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) with a Vitek mass spectrometer
(bioMérieux, Durham, NC), and automated susceptibility testing
for Escherichia coli with MicroScan WalkAway Plus (Beckman
Coulter, Inc., Brea, CA) was performed. E. coli was isolated from
3/8 aerobic bottles and 4/8 anaerobic bottles. B. fragilis was isolated from 2/8 aerobic bottles and 3/8 anaerobic bottles. C. albicans was isolated from 2/8 aerobic bottles, and C. difficile was
isolated from 3/8 anaerobic bottles.
For further identification of the anaerobic bacteria, the RapID
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ANA II system (Remel, Lenexa, KS) was used. The isolates of C.
difficile grew as small gray to yellow-white colonies with a Gramvariable rod appearance on CDC agar after initial growth in thioglycolate broth. The RapID ANA II system and MALDI-TOF MS
identified the isolates as C. difficile with 99.92% and 99.9% confidence values (CV), respectively. Identification was confirmed by
positive tests for glutamate dehydrogenase (GDH) and toxin B by
antigen testing and molecular identification of the specimen and a
dilution from the isolate using the C. Diff Quik Chek Complete
(Alere, Orlando, FL) and BD Max CDiff assay (Becton Dickinson,
Sparks, MD).
The patient was empirically started on intravenous piperacillintazobactam (3.375 mg every 12 h) and intraperitoneal (i.p.) ceftazidime (500 mg every 24 h). Upon identification of the isolates, intravenous fluconazole (100 mg every 24 h) was added. Blood cultures
yielded no growth, and intravenous piperacillin-tazobactam was
later discontinued. Although the patient’s abdominal pain improved
and leukocytosis resolved, his PD fluid cultures remained positive
with growth of E. coli, B. fragilis, and C. albicans on hospital days 1
to 3 and C. difficile on hospital days 5 to 7. Computed tomography
(CT) of the abdomen/pelvis was obtained to evaluate for abdominal perforation but was unremarkable.
Intraperitoneal ceftazidime was discontinued after identification of the organisms, and intravenous ertapenem was initiated
for improved anaerobic coverage. On hospital day 7, because of
persistent growth with Clostridium difficile, the PD catheter was
removed, and the patient improved clinically. Eventually, he was
transitioned to oral antibiotics with cefuroxime (500 mg twice
daily), metronidazole (500 mg three times daily), and fluconazole
(100 mg daily) for an additional 14 days and then discharged.
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Case Report

At outpatient follow-up 2 weeks later, clinical improvement
was noted, and the patient remained asymptomatic after finishing
the course of antimicrobials.

Peritonitis has been the main complication associated with
peritoneal dialysis and has caused significant morbidity and mortality (1, 2). The majority of peritonitis cases (50%) are attributed
to Gram-positive organisms—typically coagulase-negative staphylococci, Staphylococci aureus, and Enterococcus (3). A smaller percentage (15%) are due to Gram-negative organisms such as E. coli
and Bacteroides, and 4% of cases are mixed Gram-positive and
-negative infections. Culture-negative etiology accounts for 20%
of cases (3).
We report the first known successfully treated PD catheterrelated C. difficile peritonitis case. Similar to our case, Laroche et
al. had earlier reported isolation of C. difficile in the PD fluid of a
patient who also had polymicrobial peritonitis (4). In that case,
despite catheter removal and appropriate antibiotics, the patient
developed septic shock and died.
C. difficile is known for causing intestinal infections but is seldom found in extraintestinal locations (5). C. difficile toxin is
known to have a profound effect on colonic mucosa but is thought
to have minimal pathogenic ability outside the gastrointestinal
tract (6). The extraintestinal C. difficile infections described have
included bacteremia, abdomino-pelvic infections, wound infections with bone and joint involvement, pulmonary effusions, empyemas, and extra-abdominal abscesses (7). C. difficile is isolated
alone in only a small percentage of cases and is typically found in
polymicrobial infections, where it may play a role in enhancing the
virulence of other pathogens (6).
Because C. difficile is a fastidious anaerobe and is often isolated
with other microbes, its isolation often is difficult and challenging
and emphasizes the need for sensitive microbiologic detection
methods (8, 9). In distinction from intestinal infections, where the
diagnostic criteria are well defined, the significance of isolation of
C. difficile from extraintestinal sites can sometimes be unclear.
Initially, our patient exhibited polymicrobial growth in dialysis
fluid cultures on hospital days 1 to 4 with isolation of E. coli, B.
fragilis, and C. albicans, but as he experienced persistent abdominal symptoms, he was found to have single isolation of C. difficile
on 3 different specimens on hospital days 5 to 7, which suggests
that the isolate was indeed pathogenic.
Gupta et al. have described association of previous antimicrobial exposure and underlying comorbidities such as malignancy,
renal disease, trauma, or surgery with extraintestinal C. difficile
infections (9). Our patient had multiple comorbidities predisposing him to infection, including congestive heart failure, diabetes,
hypertension, and end-stage renal disease.
Although this association exists, in another review by Bedimo
and Weinstein, at least one-third of cases of extraintestinal C.
difficile infections had no predisposing factors (10).
Most studies propose that C. difficile enters the bloodstream or
abdominal compartment after mucosal wall breakdown or penetration (10). As a result, direct spread can occur from the intestine
or from transient bacteremia causing infection at distant locations
(7). However, infections without gastrointestinal pathology can
occur in up to 27% of cases (10). Diarrhea was found in approximately 32 to 52% of cases (8–10). Since our patient lacked a his-
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tory of diarrhea, bacteremia, recent intestinal surgery, or perforation, we think that he may have acquired the C. difficile infection
environmentally or was colonized with it, and a microperforation
that was not visible on imaging may have caused his infection.
There are no specific guidelines for the treatment of extraintestinal C. difficile infections. C. difficile isolates in most cases are
susceptible to metronidazole and piperacillin-tazobactam. Vancomycin is also frequently used in both parenteral and oral forms
(9). In one case of primary C. difficile peritonitis, successful treatment was rapidly achieved with intravenous metronidazole (500
mg intravenous every 8 h) after treatment failure on imipenemcilastatin (11). Metronidazole (500 mg oral every 8 h) for a 10-day
course also worked effectively in a patient with culture-negative
peritoneal dialysis-related peritonitis secondary to C. difficile colitis (12). Our patient was treated successfully with a 14-day course
of oral metronidazole (500 mg oral every 8 h) in addition to antibiotics directed to cover other microorganisms. Although our patient had a favorable outcome, mortality rates from these infections can be high, ranging from 25 to 37% (8–10).
Our case demonstrated that effective combination antimicrobial therapy using metronidazole and catheter removal can successfully cure C. difficile catheter-related peritonitis. Further studies may be needed to define the optimal treatment approach for
the management of extraintestinal C. difficile infections.
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